Report Summary
The diagnosed diabetic population in Australia is growing, and patients are continuing to struggle to succeed in and maintain target blood glucose levels. These market drivers, combined with a preponderance of safety issues over currently marketed antidiabetics in recent years, means the chance for brand spanking new and improved pipeline candidates is lucrative.
Browse all: Banking and Finance Market analysis Reports
Features and benefits
- Provides insight into the key drivers and resistors to antidiabetic medication uptake in Australia
- Analyzes the present diabetes treatment paradigm in Australia
- Assesses key brands within the insulin and non-insulin antidiabetics market in Australia
- Summarizes key pipeline candidates expected to launch in Australia, and their seemingly impacts
Highlights
Despite sturdy market drivers, the Australian antidiabetics market will be troublesome to penetrate, with variety of leading world brands facing restrictions in approved indications and difficulties getting reimbursement.
With restricted pipeline development within the insulin category, the foremost impact on growth can come back from the biosimilar threat, expected to require impact in Australia from 2015. Meanwhile, glucagon-like peptide-1 can acquire market share if reimbursement difficulties will be resolved and as longer-acting molecules reach the Australian market.
Oral antidiabetics can still prosper, driven by variety of late-stage pipeline candidates, as well as a replacement category of sodium-dependent glucose transporter-2 inhibitors. However, the thiazolidinedione category is predicted to lose market share to alternative oral antidiabetics with higher long-term safety profiles.
OVERVIEW OF DIABETES IN AUSTRALIA
Australia-specific diabetes epidemiology
sort one diabetes is increasing in incidence, however overall prevalence remains low
sort a pair of diabetes is extremely prevalent in Australia
Australian diabetes market drivers
The prevalence of diabetes is increasing in Australia
1/2 all Australian diabetes patients don't reach HbA1c target of <7%
The Australian government has committed important funds to diabetes analysis and management
Launch of novel compounds can stimulate the non-insulin market
Australian diabetes market resistors
Novel antibiotic could struggle to realize Pharmaceutical advantages theme listings
Biosimilars can begin to impact insulin sales
problems with safety and efficacy of thiazolidinediones have jaded some prescribers
Health reforms aim to decrease the diabetes incidence and spending by increasing preventative care and chronic disease management programs
ways to access the Australian antidiabetics market
Novo Nordisk identifies itself as a diabetes-focused company and offers support services
Eli Lilly must improve its dissemination of physician and patient education
Merck's campaign promoting Januvia to GPs ensured speedy product uptake
Related Reports:
Autistic Disorder Therapeutics - Pipeline Assessment and Market Forecasts to 2018 - http://www.reportsnreports.com/reports/131733-autistic-disorder-therapeutics-pipeline-assessment-and-market-forecasts-to-2018.html
Psoriasis Therapeutics - Pipeline Assessment and Market Forecasts to 2018 - http://www.reportsnreports.com/reports/131735-psoriasis-therapeutics-pipeline-assessment-and-market-forecasts-to-2018.html
Incoming search terms
antidiabetics market,pharmaceutical,diabetes treatment,diabetes medication,diabetic market analysis,antidiabetic report
